House of Commons photo

Track Colin

Your Say

Elsewhere

Crucial Fact

  • His favourite word is oshawa.

Conservative MP for Oshawa (Ontario)

Won his last election, in 2021, with 40% of the vote.

Statements in the House

May 12th, 2009

Mr. Speaker, it is unfortunate that we heard that partisan rhetoric from the member because autism is not a partisan issue. I myself have a son who has been diagnosed on the spectrum. I am a little disappointed at the tone the member has taken. I think all members in the House would like to do what they can for these families and these children.

The Government of Canada recognizes that autism is a serious health and social issue affecting many Canadian families and individuals from all walks of life, including parliamentarians. We do not know what causes autism. We do not know its prevalence in Canada. We do not know the effective treatments and interventions.

In order to advance any strategic work, which is what the member is talking about, to address autism, it is essential that governments and stakeholders better understand the condition, its causes and its treatments.

Accordingly the Government of Canada needs to continue its efforts in supporting a stronger, evidence base to enhance our understanding before we commit to other action.

There has been a great deal of attention toward and activity dedicated to autism over recent years and, fortunately, so too has there been increased Government of Canada action on developing knowledge and awareness about this very important condition. By way of examples, I would like to read them for the member.

In November 2007, the Government of Canada, this government, hosted a symposium devoted to autism knowledge, and yet the member says that nothing has been done. This event provided a wonderful opportunity to bring together leading Canadian researchers, policy makers and people affected by autism to discuss the latest in autism research.

With Simon Fraser University, the Government of Canada is supporting a national research chair in autism to address issues related to treatment and intervention.

The Government of Canada has also examined the establishment of an autism surveillance system through a consultation process, the results of which are currently being analyzed and will be made publicly available this spring.

This government provided funding to the Canadian Autism Intervention Research Network to support the development of updated material in both English and French and is currently providing additional funding to develop an online national survey of research priorities in autism and hold a national autism conference in Toronto this spring.

Over the last seven years, more than $27 million have been spent on autism-related research by the Canadian Institutes of Health Research.

I am confident that these activities will continue to contribute to and enhance Canada's capacity to address this important issue.

The Government of Canada welcomes the opportunity to increase information and awareness on autism and provide access to the latest information to those affected by this condition and their families.

The more we share the knowledge, the more we gain.

By transforming this knowledge and awareness into appropriate treatments and interventions, we can provide the necessary change for Canadians living with autism and their families.

I am confident that, as time goes on, the challenges posed by gaps in knowledge and lack of awareness on autism will be overcome and that we can then take appropriate action in collaboration with our provincial and territorial colleagues to address this important issue. We are committed to that.

Product Safety May 8th, 2009

Mr. Speaker, we are very proud of the action we are taking to promote the health and safety of Canadians through the chemicals management plan.

Canadians expect action. We monitor these chemicals on a regular basis. We do act appropriately when complaints occur.

Human Pathogens and Toxins Act April 30th, 2009

Madam Speaker, there are about 3,500 laboratories that import these agents into Canada and they are covered under the existing importation regulations. However, there are approximately 4,000 other laboratories in Canada that work with human pathogens and toxins, but they do not import them and they are not subject to the same federal regulation and oversight. These laboratories may be applying national laboratory safety guidelines on a voluntary basis, but the precise extent of this application is unknown.

That is why we have this legislation to ensure that Canada's reputation remains stellar worldwide.

Human Pathogens and Toxins Act April 30th, 2009

Madam Speaker, the member is quite correct. There are stakeholders who feel that this legislation, like any piece of legislation, is not perfect. However, I think the member realizes that in any type of legislation there has to be a balanced approach. We have to decide and debate what we want in the legislation and whether we want to move forward with the regulations.

I was impressed with Health Canada when it said that it would consult with us and give strong consideration to this piece of legislation through the implementation phase. We also brought forward an amendment for an advisory committee.

The member may be totally correct in saying that not all stakeholders believe that this is perfect legislation, but it did pass committee and we did have a good debate.

Overall, we have come up with a good piece of legislation, a balanced piece of legislation. The Canadian public deserves legislation that would protect their biosafety and biosecurity. This government and all opposition parties are in line with that intent, that is for sure.

Human Pathogens and Toxins Act April 30th, 2009

Madam Speaker, I would like to thank the hon. member for her wise oversight as chair of the health committee. It was through her leadership that we were able to move forward with this legislation. She was very good at working collaboratively and developing consensus with the different witnesses as well as the members of committee. I thank her for that.

She brings up a very important point. It was acknowledged that the intent of the legislation was to treat risk group 2 human pathogens differently than groups 3 and 4, so it was very important to clarify exactly what was meant. There were three amendments included that recognized that facilities dealing only with risk group 2 human pathogens should be treated less stringently under the bill, the program and regulatory framework, as they are less risky than human pathogens in risk groups 3 or 4 or toxins.

There was also an amendment included which specified that there will be no requirement for security screening of persons with access to only risk group 2 human pathogens, as well as an amendment to lower the possible penalties for contraventions of the act or regulations involving only risk group 2 human pathogens.

The government also proposed two further amendments to respond to the concerns expressed by the Privacy Commissioner and moved those forward as well. I hope that answers the hon. member's question.

Human Pathogens and Toxins Act April 30th, 2009

Madam Speaker, this very issue was brought up in committee. There was concern with some of the researchers who were working with these pathogens and toxins. As the member would know, even though researchers working in laboratories take the utmost precautions, spills can occasionally happen.

The intent of this legislation is not to force laboratories and workers to report what we would call usual spills in conducting their research but if there are inadvertent releases from the laboratory into the public domain. The idea of this legislation is to improve biosafety and biosecurity in Canada. There is still a very strong concern that these pathogens and toxins will not be released to the general public and will not cause a concern to our health and safety in Canada.

This was something put forward by the government and that all opposition parties were in agreement with. We were happy to clarify that wording because that definitely is the intent.

Human Pathogens and Toxins Act April 30th, 2009

Madam Speaker, indeed, the member is correct. The NDP critic worked very hard and co-operated with the government and the entire committee to move this very important piece of legislation forward.

As I said in my opening statement, I want to thank all the critics and members of the committee, the NDP, Bloc and Liberals. By working together, we came up with an improved piece of legislation.

The amendments that the NDP member put forward were included. We listened to her suggestions because we felt it made a better piece of legislation and I want to publicly thank her for her input and good work.

Human Pathogens and Toxins Act April 30th, 2009

Madam Speaker, I want to start off by taking the opportunity to thank the opposition parties, especially the critics from the NDP, the Bloc and the Liberal Party, for all their hard work and co-operation in working on this very important piece of legislation.

I am pleased to be here today to update members on the progress of Bill C-11, An Act to promote safety and security with respect to human pathogens and toxins.

As we have heard at second reading, there is strong support for strengthening safety and security with regard to human pathogens and toxins in Canada.

We had an opportunity at the Standing Committee on Health to discuss the key elements of the bill, which would provide the new authorities required to safeguard Canadians from the risks that dangerous human pathogens and toxins pose.

The Standing Committee on Health heard from a wide variety of witnesses about the importance of Bill C-11. Following witness testimony, as well as appearances by government officials from the Public Health Agency of Canada, amendments were made to Bill C-11 that have strengthen the bill and addressed many of the concerns raised by witnesses.

I would like to give members a quick overview of the bill.

The intention of the bill is to try to balance biosafety and biosecurity requirements with the need to advance science and research. The intent of the bill is not to restrict research and development, but rather to introduce a risk-based approach to the management of human pathogens so that they are handled safely and accounted for across Canada.

Because of the risk posed by dangerous human pathogens and toxins, Bill C-11 relies primarily on the criminal law jurisdiction of Parliament. In this regard, Bill C-11 includes a range of prohibitions, penalties and security screening requirements designed to protect the health and safety of Canadians.

The program and regulatory framework to be developed under Bill C-11 will include requirements for licensing, inventories, biological safety officers, information gathering and transfers of human pathogens and toxins, among other matters. The legislation has been drafted with care to ensure that the bill fully respects the rights and freedoms of Canadians entrenched in the Charter of Rights and Freedoms and privacy rights protected via the Privacy Act.

There were certain amendments to the bill. In studying Bill C-11, several issues were raised from various witnesses concerned about the impact of the bill on their work. These issues included concerns about the oversight of risk group 2 laboratories, concerns about how the suite of regulations for Bill C-11 would be developed, concerns about the reporting requirements, as well as concerns about the schedules under the bill and how they would be amended over time.

We listened to these concerns, and I believe we have worked together at the health committee to develop a piece of legislation that addresses these concerns and more precisely reflects the original policy intent of Bill C-11.

Now I would like to speak about risk group 2.

With regard to the concerns that the committee heard about the oversight of risk group 2 human pathogens, several amendments were made to clarify that these relatively less harmful agents would be treated less stringently than the more dangerous risk groups 3 and 4 human pathogens, in the bill and in the program and regulatory framework. Four specific amendments were made for this purpose.

The first amendment clarifies in the preamble that human pathogens and toxins pose varying levels of risk to the health and safety of the public. This change reflects what was heard in committee, that not all human pathogens and toxins are the same from the perspective of risk, that some pose a greater threat than others.

The second amendment dealing with risk group 2 agents clarifies clause 33 explicitly so that security clearances will only be required for persons who have access to prescribed risk groups 3 or 4 agents or toxins as prescribed in regulations. It was never the program policy intent to security screen individuals who only have access to risk group 2 human pathogens, and this amendment clarifies this intention.

The third amendment regarding risk group 2 agents creates lesser general penalties for offences under the act or regulations related to risk group 2 human pathogens. This includes no provision for a prison sentence for a first offence involving only risk group 2 agents. This change to clause 53 reflects concerns voiced that persons carrying on activities with risk group 2 human pathogens should be treated more leniently than those carrying on activities with risk groups 3 or 4 human pathogens.

Finally, the fourth amendment, in clause 66, makes explicit that the regulatory regime will treat risk group 2 human pathogens in a way that is consistent with the fact that they are less dangerous than human pathogens in risk groups 3 and 4. Taken together, these changes signal that the level of risk associated with risk group 2 human pathogens is lower than risk groups 3 or 4, and they will therefore be treated less stringently in the overall legislative and regulatory framework.

Regarding reporting requirements, another important amendment that was made at the health committee clarifies that subclause 12(1) of the bill only applies to releases of human pathogens or toxins from a facility. This stems from concerns that were heard from stakeholders that minor spills contained within a licensed facility would have to be reported. This amendment recognizes that releases from the facility itself pose greater risks to public health. Once again, we believe this will help to improve the clarity of the bill, specifically with regard to what will be required of licensees.

Another important amendment requires the formation of scientific advisory committees under clauses 9 and 10 to advise the minister regarding changes to the lists of human pathogens and toxins found in schedules 1 through 5. As part of the consultations on the program and regulatory framework, the Public Health Agency of Canada will consult with stakeholders concerning the makeup of these committees, which be will formed under the authority in section 14 of the Public Health Agency of Canada Act.

Concerning privacy amendments, during hearings on Bill C-11, the health committee received a letter from the Privacy Commissioner noting, amongst other things, the need for a more objective test of what constitutes relevant information collected by the minister under clause 38, as well as the need for situations in which recipients of information disclosed by the minister pursuant to subclause 39(2) may be compelled by law to disclose it further. These two amendments were made based on suggestions from the Privacy Commissioner.

The last of these important amendments requires the tabling of the regulations in both houses of Parliament. This amendment reflects what we heard from witnesses about the need for greater accountability and transparency in the making of regulations. In reviewing the wording of this particular amendment, the government noted some inconsistencies between the intention of what was stated in the health committee and what was written into the revised Bill C-11.

Specifically, it was agreed that the amendments would require tabling of the regulations in both houses of Parliament in order to provide an opportunity for review by a committee in each house. The wording of the bill after committee stage only required the referral of the proposed regulations to a committee in the House of Commons. There was no similar requirement regarding the referral of the regulations to an appropriate committee in the other place.

The government therefore clarified that the regulations would need to be tabled in both houses of Parliament and referred to a committee of each house. We believe this was the original intention of committee members in agreeing to this amendment, and we tabled an amendment at report stage from committee to clarify this intention.

There is a need to move forward. We believe this new legislation is needed now. It is required to safeguard the health and well-being of all Canadians, including those persons working in laboratories. It is also required to demonstrate to the Canadian public and to our international partners that the Government of Canada is taking the issue of security related to human pathogens and toxins very seriously. The proposed legislation represents a made-in-Canada approach that addresses both safety and security.

Clearly, the urgency in moving ahead with expanded federal oversight over human pathogens and toxins has been widely recognized. I believe the study of Bill C-11 in the health committee has resulted in a clear piece of legislation, and I look forward to moving it on to the Senate.

Canada Consumer Product Safety Act April 29th, 2009

Mr. Speaker, to give the member a bit of my history, I was one of the members who brought forward Bill C-420, which was a natural health products bill. I continue to be involved with that community.

In the original writing of the bill and in the past version, Bill C-52, there was some confusion in the language and stakeholders from the natural health products community required some clarification of it. The minister has written to the chair of the health committee. We will be putting forward an amendment to clarify that exactly so that the stakeholders from the natural health products community know that this bill excludes natural health products and food and drugs under the Food and Drugs Act.

Canada Consumer Product Safety Act April 29th, 2009

Mr. Speaker, I would like to thank the member for her question and for her good work on the health committee.

She is bringing up something that is handled both in the Hazardous Products Act and in CEPA. With this new legislation, there is going to be some crossover between the two pieces of legislation. The government will study this to see what are environmental issues, what is going to be handled under the new act and take appropriate action as required.

I hope that answers the member's question.